Clinical Study
Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study
Table 3
Efficacy of PSR 15 mg and PSR 30 mg against relapse of P. vivax malaria.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg. Denominator used is the number of patients who had completed treatment period of 14 days (for P 15 mg, ; for PSR 15 mg, ; and for PSR 30 mg, ). PSR 15 mg and PSR 30 mg compared with P 15 mg conventional using Fisher’s exact test. Denominator used is the total duration of follow-up in years (calculated based on total number of follow-up days). Value shown is a conditional exact 95% CI for ratio of two Poisson variables. Percentage reduction in incidence rate of PSR 15 mg and PSR 30 mg compared with conventional P 15 mg. NA: not applicable value. |